Abstract
Background Chronic breathlessness profoundly affects quality of life for its sufferers. Often, reported breathlessness is inconsistent with airway pathophysiology and objective disease markers. While a mechanistic understanding of this discordance has thus far remained elusive, factors such as mood, attention and expectation have all been implicated as important perceptual modulators. Therefore, here we have developed a model capable of exploring these relationships aiding patient stratification and revealing clinically-relevant neuro-biomarkers.
Methods A cohort of 100 participants with mild-to-moderate chronic obstructive pulmonary disease (COPD) underwent a comprehensive assessment that included functional brain imaging while viewing and rating breathlessness-related word cues, self-report questionnaires and clinical measures.
Results Using an exploratory factor analysis across psychological and physiological measures, we identified two distinctive neuropsychological behavioural profiles that differed across four key factors corresponding to mood, symptom burden, and two capability measures. These profiles stratified participants into high and low symptom groups, which did not differ in spirometry values. The low symptom load group demonstrated greater FMRI activity to breathlessness-related word cues in the anterior insula.
Conclusions Our findings reveal two clear groups of individuals within our COPD cohort, divided by behavioural rather than clinical factors. Furthermore, indices of depression, anxiety, vigilance and perceived capability were linked to differences in brain activity within key regions thought to be involved in monitoring bodily sensations (interoception). These findings demonstrate the complex relationship between affect and interoceptive processing, providing the foundations for the development of targeted treatment programmes that harness clinical and symptom-relevant biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
not a clinical trial
Funding Statement
This work was supported by the Dunhill Medical Trust (Grant R333/0214) and the National Institute for Health Research Biomedical Research Centre (Grant RCF18/002) based at Oxford University Hospitals NHS Foundation Trust and The University of Oxford. CJH is supported by the National Institute for Health Research Biomedical Research Centre based at Oxford Health NHS Foundation Trust and The University of Oxford, and by the UK Medical Research Council.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Footnotes
sarah.finnegan{at}ndcn.ox.ac.uk, faull{at}biomed.ee.ethz.ch, kyle.pattinson{at}nda.ox.ac.uk
Data Availability
Data available by contacting authors subject to data sharing policies of the Nuffield Dept Clinical Neurosciences
